text:
Drunk driver can't keep auto on road
Gus Philpott
Woodstock Advocate
December 29, 2011
This morning's paper reports an off-the-road crash of an unlicensed drunk driver in McHenry, and further bad luck for a family whose daughter was the victim of a hit-and-run in McHenry only a few days ago.
Jesus Torres-Arellano, 34, crashed his vehicle into a van parked in a driveway early Christmas morning. Think he might have been out celebrating a little too much?
McHenry Police charged him with driving under the influence, summary suspension, driving without a license (or never issued a license), operating an uninsured vehicle, failure to reduce speed (to avoid an accident), and improper lane usage. (Hey, you can't suspend my license! I don't have a license!)
The license plate came off his car, according to the newspaper report, so the cops' investigation was pretty short and easy. Torres-Arellano has a court date on February 6.
Think anyone will check to see if he is in the USA legally? Let's see; looks like a Mexican surname, no driver's license; no insurance. Tch, tch, is this racial profiling?
Where was he before he took on the van in the driveway? Drinking in a bar? Partying in a private home? Didn't anyone notice he was drunk and try to take away his keys?
Well, at least he probably won't be on the road on New Year's Eve.
|Connect with The Crittenden Automotive Library


text:
After releasing a demo that wasn't really one according to some, Polyphony is back with this video of Gran Turismo 5 presenting the Mercedes Benz SLS AMG. A lot more impressive, as usual with the trailers of the game.
$224 of $400 per month
Become a patron →
Resident Evil 3 - Special Developer Message: [url] Confirms it's 3rd Person View, has more details and additional footage - including Dodge. (2 Hours ago)
speaking of , what do you make of this? [url] (3 Hours ago)
@KORNdog: nothing has been scarier than my first encounter with Lisa from P.T. (3 Hours ago)
@HR2: yeah, nemesis looks friggin hilarious now with his popsicle stick teeth and wonky nose (4 Hours ago)
However, it's coming to PC, I bet a modder will mod it to look even better - more terrifying - in a matter of days. I will never forget MR. X in a thong. *chills* (5 Hours ago)
Nemesis new look is fine, though I preferred the original. Maybe nostalgia talking, will need to see more of the new design, specially in action. (5 Hours ago)
Either way, we're getting both, so if Resistance sucks, RE3R will be more than enough. I wonder what Capcom will remake next, RE1, RE:Code Veronica, RE0 or RE4. RE4 Remake would be a dream!!! (5 Hours ago)
GSY is getting some nice content at 3 pm CEST with our July podcast and some videos of the Deus Ex Mankind Divided preview build. :) (> 3 Months ago)
For once we'll be live at 4:30 pm CEST. Blim should not even be tired! (> 3 Months ago)
More Quantum Break coverage coming in a few hours, 9:00 a.m CEST. (> 3 Months ago)
We'll have a full review up for Firewatch at 7 pm CET. Videos will only be tomorrow though. (> 3 Months ago)
Tonight's livestream will be at 9:15 GMT+1, not GMT+2 as first stated. (> 3 Months ago)
New GSY Live dedicated this time to Just Cause 3 on Tuesday 9:30 GMT+2 (> 3 Months ago)
Join us tomorrow at 10 pm GMT+2 for a new livestream. We'll be playing Rise of the Tomb Raider. (> 3 Months ago)

subset: commoncrawl


text:
hi greg, sounds like ap. sorry to break the news to you, but it is better going into your doc with an idea than without one. if you are near philly, go to see meyers. if you are near nyc, then there are a few docs in the area that can help diagnose it (west orange, nj orthopedic group), i think.
the pains sound like the pains from the nerves affected by ap. but i am no doctor, just saying from experience that your symptoms sound the same as ap.
get it looked at asap but trust only the experts to do surgery, don't let any doc school themselves on the injury with your body. regular hernia guys usually cannot fix sports hernias, you need an ap surgeon.
hope it helps.


text:
Mac users - do not upgrade to OS X Mountain Lion
Apple will soon release its new OS X Mountain Lion operating system. Although the upgrade promises to deliver great new features, it has not yet been fully vetted for compatibility with the UCSF computing environment. Those who try to install Mountain Lion may experience significant problems, especially with encrypted computers.
For this reason, please do not upgrade to OSX Mountain Lion until we confirm that it is compatible with encryption, anti-virus, VPN, backup, remote control, Office, and other software products used at UCSF.
If you have any questions please work with your departmental IT service provider or contact the IT Service Desk at: [email protected] or (415) 514-4100.
- 3649 reads
- Printer-friendly version


text:
Home » Uncategorized » Stepping Up My Quiz Master Game
Stepping Up My Quiz Master Game
|April 11, 2015
|Posted by Wes Hazard under Uncategorized
This might be my favorite image of me ever. Thanks to "Balsamic Winaigrette" winner of last night's Best Smart-ass Point of the night during April's The Big Quiz Thing show at Oberon in Cambridge. This was their answer to a question asking them to identify a photoshopped image of radio/TV legend Joe Franklin wearing Yves St. Laurent.
They got the huge ears and bulging left-breast pocket and everything. And were nice enough to point out that my microphone was in fact NOT a penis. Thanks to all.
Be sure to check out our spectacular May the Fourth Be With You spectacular, an entire evening of Star Wars Themed trivia, 5/4 8pm @ Oberon.


text:
Reed Krakoff, former Coach mastermind and recent cautionary tale after his much-hyped, self-titled women's wear brand closed in 2015, is back — and having breakfast at Tiffany's.
On Tuesday, Tiffany & Company announced that it was naming Mr. Krakoff to the new post of chief artistic officer, making him the first designer in the heritage jeweler's 180-year history to become part of the company's executive suite. His responsibilities will include jewelry, luxury accessories and all imagery, including that used in stores, e-commerce and advertising.
When you think about it, that's a pretty big deal.
Not just because there is a tradition in fine jewelry to keep the designer in the background and to make the gem the star. (Can you name the head of design for Cartier? Van Cleef & Arpels? Bulgari? Thought not.)
Not just because the news — which was foreshadowed last year when Mr. Krakoff became a creative consultant for the company, focusing on a line of holiday gifts, homeware and accessories — marks a gilded return to luxury for Mr. Krakoff, who has no formal training in jewelry.
But because the position includes more power than any creative figure has had at Tiffany, including its recent design director, Francesca Amfitheatrof, whose remit was limited to Tiffany-branded jewelry, and who will be leaving the company. Even John Loring, Tiffany's longtime former design director, played less of a strategic role. Famous collaborators such as Paloma Picasso and Frank Gehry made only special collections for the brand.
And thus it underscores a recent trend in high-end fashion toward empowering the design side of the business. Since 2004, when Tom Ford left Gucci to much industry hand-wringing, conventional wisdom has held that brands should be more important than the people behind them. But the pendulum has begun to swing in the other direction.
In August, Calvin Klein named Raf Simons its chief creative officer, the first time that all of its lines were united under a single design authority since Mr. Klein sold the business in 2002. Last summer, Maria Grazia Chiuri was named artistic director of Dior women's wear and given an expanded portfolio that included not just runway shows but also image, ads and stores. Both appointments echoed the iron-fisted control over all things consumer-facing that was given to Hedi Slimane during his tenure at Yves Saint Laurent, during which he famously transformed that brand into one of the fastest-growing names in the parent company Kering's portfolio.
Presumably, Tiffany is hoping that Mr. Krakoff will do the same. It could use some help, after all.
The Fifth Avenue jeweler has not been exempt from the general slowdown in the luxury market that has been in effect for the last few years. In 2015, worldwide net sales declined 3 percent, to $4.1 billion. Though there were some improvements in 2016, Frederic Cumenal, the Tiffany chief executive, said on Tuesday thatperformance during the holiday period was "somewhat lower than we had anticipated." To a certain extent, the company has become stuck in a blue box of its own making.
Efforts have been made to add some contemporary pizazz via Ms. Amfitheatrof's designs, which were worn on the red carpet by celebrities such as Cate Blanchett. The house also brought in the punky new-gen jeweler Eddie Borgo for a special line, embarked on a collaboration with the hip emporium Dover Street Market, and enlisted Grace Coddington, the former Vogue creative director, to style an ad campaign. But the initiatives often seemed disjointed and inconsistent. Mr. Krakoff will, at the very least, provide a single, overarching point of view.
It is this clarity of vision and direction that increasingly seems to draw consumers to a brand, and it was part of what Mr. Krakoff brought both to Coach and to his own line (though in an interview this year, he acknowledged that the latter perhaps took itself a bit too seriously for its own good).
Less clear, however, is how Mr. Krakoff, who is known for his way with leather and cashmere and who has a penchant for architecture and high-minded modernism, will handle diamonds and pearls. According to Luca Solca, an analyst for Exane BNP Paribas, "designing handbags and designing jewelry are two different things" and, certainly, Mr. Krakoff is relatively unproven when it comes to the latter.
Nathan Strauss, director of corporate communications for Tiffany, said the company was not concerned about Mr. Krakoff's lack of experience with jewelry.
"Reed understands luxury, and the impeccable purity of design required for jewelry," Mr. Strauss said. "He is famous for his decades of experience designing accessories for the body, as well as objects for the home. Reed has dedicated his life to fashion and design, and looks forward to applying his passion for jewelry and gemstones in this new role."
Besides, the biggest risk in luxury these days is often considered to be taking no risks at all.
Mr. Krakoff starts Feb. 1.


text:
If you're ready to change the color of your home inside or out, choose Infinity Painting LLC for painting services. Our professional painters utilize extensive experience to paint your home carefully. We use low VOC paint for minimum odor.
Tell the professional painters at Infinity Painting about your residential painting job today. We offer painting services to residents of the Hamden & New Haven, CT area.
At Infinity Painting, we're dedicated to completing every aspect of your painting project. Our professional painters will:


text:
Women in Executive Leadership Program – Faculty
Pam Keith
Born to a U.S. Navy family, Pam Keith had the privilege of growing up in various US diplomatic communities around the world. Through her worldly upbringing, she learned at an early age the value of being an American. Her family finally settled in Lexington, Kentucky, where her family was the only African-American family in the neighborhood. Those experiences would fuel her passion to fight for equality and justice for years to come. Pam completed undergraduate and graduate study at U.C. Davis, then traveled cross-country to earn her J.D. at Boston College Law School. From law school, Pam was commissioned into the United States Navy as a Judge Advocate. She was stationed both domestically (DC, Virginia) and abroad (Bahrain), where she passionately worked on military justice cases. Following the Navy, Pam practiced law for some of the most prestigious firms across the United States. Today, she is committed to advocating for those with no voice. She is an engaging speaker on the topic of women, leadership, and taking risk.
Kevin Cox, Ph.D., Kevin Cox has a Ph.D. in Entrepreneurship from Florida Atlantic University's College of Business. Prior to pursuing his Ph.D., Kevin received his degree in Management, with minor in Entrepreneurship as well as a Master of Science in Entrepreneurship from the University of Florida. Currently, he serves as the Assistant Director for the Adams Center for Entrepreneurship at FAU, Entrepreneurship Professor, instructor for the new venture accelerator at FAU's Tech Runway, instructor for FAU's entrepreneurship bootcamp, manager/instructor for FAU's Veterans Florida Entrepreneurship Program, and Faculty Adviser for FAU's student entrepreneurship club, Owls Inc. To date Kevin has taught, mentored, and worked with over a hundred startups providing expert advice and consultation support the survival, growth, and performance of these early stage businesses. He has also published multiple research papers and book chapters, as well as dozens of conference papers on entrepreneurship.
Joel M. DiCicco, PhD, CPA, is full-time faculty for FAU's Executive MBA program, as well as adjunct faculty for the Thomas Jefferson School of Law Graduate LLM Program. He is a CPA with over 30 years of practitioner experience in finance, taxation and accounting. Previously, Joel was a program manager for the Internal Revenue Service's Global High Wealth and Financial Products industries. Joel holds the Personal Financial Specialist, Chartered Global Management Accountant, and Certified in Financial Forensics certifications from the American Institute of Certified Public Accountants and the Business Certified Appraiser designation from the International Society of Business Appraisers.
Monica Escaleras, Ph.D., is an associate professor of Economics and is the founder and Director of the Business and Economics Polling Initiative (BEPI) in the College of Business at Florida Atlantic University. Monica's scholarship focuses on natural disasters and political economy and her research has been published in numerous journals, including the Journal of Public Economics, Canadian Journal of Economics, Public Choice and Southern Economics Journal. She teaches Macroeconomics and Money and Banking. Monica earned her bachelor's degree from Kentucky Wesleyan College, her master's degree from the University of Florida and her Ph.D. in Economics from Florida International University. Prior to joining Florida Atlantic University, Dr. Escaleras was an Assistant Professor at College of Charleston.
Sofia Johan, Ph.D., LL.B, & LL.M, will be joining FAU faculty Fall 2018 in the department of Finance. Sofia is the Extramural Research Fellow at the Tilburg Law and Economics Centre (TILEC) in the Netherlands and also Adjunct Professor with the Schulich School of Business at York University. She is associate editor of the British Journal of Management. Her research is focused on law and finance, sovereign wealth funds, market surveillance, corporate governance, and alternative investments including but not limited to hedge funds, venture capital, private equity, real estate investment trusts, and IPOs. Her research has been published in the American Law and Economics Review, Journal of Financial Economics, Journal of Banking and Finance, European Financial Management, European Economic Review, and Entrepreneurship Theory and Practice, among others. She has co-authored the books Venture Capital and Private Equity Contracting, and Hedge Fund Structure, Regulation, and Performance around the World. She has also consulted for a variety of governmental and private organizations in Canada, Australasia, and Europe.
Ting Levy, Ph.D. is a senior instructor of Economics in the College of Business at Florida Atlantic University. Ting's research area is International Trade and International Economic Development. Her research has been published in numerous journals such as International Review of Economics and Finance, International Journal of Economic Theory, The B. E. Journal of Economic Analysis & Policy, Theoretical Economics Letters and American Behavioral Scientist. She teaches Microeconomics, Macroeconomics, International Economic Development, International Trade and Managerial Economics. Ting earned her bachelor's degree from Huazhong University of Science and Technology in China, her master's degrees from Carleton University in Canada, University of Florida and her Ph.D. in Economics from University of Florida.
Karen E. Pfeffer is a leadership expert who was born and raised in Venezuela until the age of 15 by a father from Kansas and a mother from Puerto Rico, giving her a unique cultural mix that has inspired her to challenge stereotypes and capture opportunities. After earning her business degree from Florida Southern College, she entered the male-dominated field of banking and became the first woman president of the Florida Bank Marketing Association. Subsequently, she founded a full-service marketing and advertising agency, which provided a broad range of strategic and creative marketing for local, national and international clients. She also became a certified practitioner of Neuro-Linguistic Programming (NLP), and was certified in basic and advanced PSYCH-K. In 2006, she co-founded Fire Power Seminars to provide communication, empowerment, team building and transformation programs through high-impact experiences.
Connie Phelan is a breakthrough coach and keynote speaker who has a passion for boldly challenging and helping people and groups achieve positive, lasting change. Connie's experience playing sports at a national level shaped her lifelong desire to help others build strong teams. She has owned her own printing company and worked in advertising for Fortune 500 companies. She had a life-changing experience when she completed her first firewalk and decided to become a certified firewalk instructor. Subsequently, she founded Fire Power Seminars in 2006 to help people gain awareness of self-limiting beliefs and patterns, and, ultimately, generate successful, long-term changes.
Nancy Proffitt is a nationally recognized business coach, author, and keynote speaker. She is also an adjunct professor at FAU, where she focuses on High-Impact Leadership Development. With 20 years in senior management with FedEx Corporation and over a decade working with business clients, she has earned recognition as a "TOP 100 Leader in Fortune 100 Business." Nancy works with clients to prepare effectively for the future, improve employee performance, and create opportunity thinking. She helps individuals and organizations become high-impact leaders, improve corporate culture, drive best practice productivity and increase employee engagement.
Emily Sacks, Ph.D. is a senior instructor in the Business Communication Department at Florida Atlantic University.
Nina Segura is a strategic management consultant, coach, business owner, and author who works with clients to achieve transformational change. After nearly 20 years at American Express leading global programs, Nina took on the challenge of building her own multi-million dollar company dedicated to keeping billion-dollar companies and their leaders relevant. Nina is trained as a Co-Active and a Massachusetts Institute of Technology – Society for Organizational Learning, North America Leadership Graduate and Certified Professional Coach with the International Coach Federation. Additionally, her work includes Everything DiSC suite of products, MBTI® Personality Assessment, Co-Active® Dimensional Leadership Model™ and Leadership SuperPowers™.
Ethlyn Williams, Ph.D. is an expert in organizational behavior and human resource management. Prior to joining the faculty at Florida Atlantic University, she was a member of the faculty at the University of South Florida and at the University of Colorado at Colorado Springs. Ethlyn teaches taught Human Resource Management, Leadership of Teams, Organizational Behavior, Principles of Management, Project Management, and Organizational Theory. Ethlyn has published book chapters on formal mentoring, psychological contracts, and measurement issues in international research. Her research also appears in the following journals: Academy of Management Journal, Human Relations, Journal of International Business Studies, Journal of Management Education, Journal of Organizational Change Management, Journal of Vocational Behavior, and The Leadership Quarterly. She is an active member of the Academy of Management, the Society for Human Resource Management, and the Southern Management Association.
All participants will be matched with a C-Suite level mentor and will also be required to become a mentor to an up-and-coming achiever. FAU is currently recruiting successful executive-level mentors to commit to mentoring one to two participants through the duration of the program. If you would like to be considered as a mentor, please contact Paige Garrido at email@example.com.
Contact Us
Paige Garrido
Assistant Director, Corporate Training and Talent Development
phone: (561) 297-4819
email: firstname.lastname@example.com
map: BU 86 203


text:
"Our mission is to make solar energy a
mainstream energy source and realize
the full potential of the Solar Industry in the
state of Tennessee."
- TenneSEIA Executive Committee
& Board Members
"Our mission is to make solar energy a
mainstream energy source and realize
the full potential of the Solar Industry in the
state of Tennessee."
- TenneSEIA Executive Committee
& Board Members
Hot News
First Solar to build 227 megawatt solar farm
TUSCUMBIA — The Tennessee Valley Authority has announced an agreement with a Houston, Texas, company to develop a 227-megawatt solar farm in Colbert County. The facility is one of two new solar farms that will provide TVA with more clean energy. The utility is already purchasing power from a 75-megawatt solar farm operated by NextEra Energy in Lauderdale County.
TVA announces solar farms to serve Google data centers
Two big new solar farms — one in Tennessee and one in Alabama — will provide carbon-free renewable power for tech giant Google's data centers in those states, the company and the Tennessee Valley Authority announced Wednesday. NextEra Energy Resources, based in Florida, is building one solar farm in Hollywood, a town in the northeast corner of Alabama. NextEra will own and operate the completed facility through a subsidiary, company spokesperson Lisa Paul sai
TVA names head of Canadian power generation company new president, CEO
KNOXVILLE, Tenn. (WATE) – The Tennessee Valley Authority announced Thursday it has named a new president and CEO to replace retiring incumbent William D. Johnson. Jeffrey Lyash, 57, will become president and CEO of TVA effective in April. Lyash is currently the president and CEO of Ontario Power Generation Inc., one of the largest electrical generation companies in Canada.
Hanwha Q Cells Korea Announces Solar Module
Hanwha Q Cells Korea Corporation announced today that it will build a solar PV module manufacturing facility in Whitfield County, Georgia. Construction will commence in 2018, and the facility is scheduled to be completed in 2019.
2018 Solar Champion
"TenneSEIA is proud to present our Solar Champion awards to the Mayor Bernie Ash of the City of Lebanon and Jeff Dykes of BrightRidge, who both exhibited an extraordinary commitment to deploying solar energy," said TenneSEIA President, Matt Beasley.
2018 Lifetime Achievement Award
Gil Hough, Renewable Energy Manager for RSI EnTech, LLC (RSI), was recently presented with the Tennessee Solar Energy Industries Association (TenneSEIA) 2018 Lifetime Achievement Award.
This Award was presented to Gil during the Tennessee Valley Solar Conference on Wednesday, November 7, 2018. Gil co-founded TenneSEIA in 2010, and he currently serves as the Executive Director. Gil is a leader and advocate for increasing responsible solar energy deployment in the Tennessee Valley region across all solar markets. His involvement and influence in solar ranges from residential and commercial, to utility-scale projects. He also has led or worked with various stakeholder groups, including the TVA IRP planning committees. In addition, Gil's work at the Southern Alliance for Clean Energy, RSI, and TenneSEIA, has advanced solar energy throughout Tennessee.


text:
Body Calm Cream 8 Oz Organic Shea Butter
Relax tense muscles and relieve aching neuropathy & fibromyalgia with our premium pain relief skin cream.
Pain happens to us all, especially as we get older. The longer we live the...read more
Average Customer Rating
|4.5 out of 5
Product Features
- MOTHER'S DAY SPECIAL - Buy 2 Get 15% Off, Use Coupon KLPROM15 at Checkout! SATISFACTION GUARANTEE: We believe that we've made the best pain relief cream on the market, however, if you aren't completely happy with your order simply return it within 30 days for a full refund.
- REDUCES NEUROPATHY & FIBROMYALGIA: Kerah Lane's Body Calm Cream helps reach deep into sore muscles, joints, and tendons to provide you ultimate pain relief. Also helps sufferers of rheumatoid arthritis, tennis elbow, fibro, plantar fasciitis, bursitis, back, neck, shoulder, knee, feet, foot, ankle, wrist, leg, nerve, sciatic pain & more
- ABSORBS QUICKLY & WORKS FAST: Our natural & organic based topical formula goes on smooth without feeling greasy and absorbs into the skin quickly so you can enjoy fast relief. Unlike other products and treatments, our ointment contains no parabens, is animal cruelty free, vegan friendly and doesn't leave you smelling like a chemical factory!
- HELPS TO RELAX & UNWIND: Keep those sore and stiff problem areas, warm and relaxed whilst at work or play, during a workout at the gym, or use to help relax after a long day. Great for use after pilates, yoga, sports, football, basketball, baseball etc. The cream is made with an anti-inflammatory and special circulation booster formula that helps calm strained joints and muscles so you can handle whatever life sends your way.
- PURE ORGANIC INGREDIENTS: We only use a premium blend of powerful pain relieving Essential Oils, Arnica and MSM to help provide you true relief and relaxation. It carries a comfortable, subtle smell of lemongrass that's safe on sensitive skin. Can also be used with knee braces, arm bands / patch to provide added relief.
Product Description
Relax tense muscles and relieve aching neuropathy & fibromyalgia with our premium pain relief skin cream.
Pain happens to us all, especially as we get older. The longer we live the more we are likely to succumb to sports injuries like Tennis Elbow, or suffer from joint point like neuropathy. Whatever the reason for your muscle and joint pain, we at Kerah Lane want to do our part to start making you feel better, faster. That is why we created this Kerah Lane Body Calm - Pain Relief Cream with Shea Butter.
Acting both as a pain relief and an anti-inflammatory cream, our organic blend of Shea butter, Arnica, MSM and Lemongrass helps to reduce your pain quickly so you can get back to enjoying your life. Our smooth, non-greasy, non-irritating formula is perfect for getting you back on your feet and working with your hands once again. Get your Kerah Lane Pain Relief Cream today and see for yourself.
Key benefits of Kerah Lane Body Calm Cream:
Pure and Organic
Fast Absorbing Pain Relief
Non-Greasy, Non Irritating
Neuropathy Pain Relief
Natural Ingredients Include:
Shea Butter
Arnica Cream
LemongrassFind real Neuropathy Relief by clicking Add to Cart now. ....read more
Bestselling Products on Amazon
Prices are accurate as of December 10, 2019 12:24 pm. Product prices and available are subject to change. Any price and availablility information displayed on Amazon.com at the time of purchase will apply to the purchase of any products.
Certain content that appears on this site comes from Amazon Services LLC. This content is provided 'AS IS' and is subject to change or removal at any time.


text:
Please enter the email address for your account. A verification code will be sent to you. Once you have received the verification code, you will be able to choose a new password for your account.
To find out about special discounts and current offers
If you wish to disable them, please take a look at our Cookies Policy. Learn more
Privacy Policy
Copyright © 2015 SAMEP Tools Powered by EcstoreWeb


text:
Navillum Nanotechnologies Invited to Prestigious Display Symposium
Navillum Nanotechnologies, a resident company at BioInnovations Gateway (BiG) has been selected to present a prototype of their technology at I-Zone (Innovation Zone) Display Week 2017 in Los Angeles later this month, a prestigious opportunity in the display field.
At this symposium, the Society for Information Display provides a forum for live demonstrations of emerging information display technologies and related areas. The I-Zone intends to showcase the cutting-edge demos and prototypes that will lead to the products of tomorrow.
"We are thrilled about being selected to showcase our quantum dot technology with other emerging display technologies at the I-Zone" said Jacqueline Siy-Ronquillo, Co-founder and CTO, Navillum Technologies.
Navillum's night vision compatible quantum dot (QD)-based film optic is a multi-purpose film solution that addresses important problems in aviation displays, including safety, clarity and efficiency. The films are customized to meet D65 white point requirements in avionics displays and can also be customized for a variety of other display technologies. The films use QDs that are produced using Navillum's patented low-temperature thermodynamic driven synthesis process.
This process enables an unparalleled degree of control over nanoparticle size, shape and overall uniformity, which is critical to the resulting optical properties of the final QD application, explained Siy-Ronquillo. Navillum offers QDs both in solution (ex. pre-polymer solution of acrylate, urethane or silicone) and in films, including cadmium-free options.
"The USTAR Life Science Incubator is committed to ensuring that talented innovators in Utah thrive. Navillum exemplifies our mission, and we are excited that the company was chosen to exhibit its latest quantum dot-based prototypes to leaders in the lighting and display industry", said Marytheresa Ifediba, BiG Life Science Program Manager.< Back to All Articles


text:
With the fun show of the mother of all social network IPOs finally behind us, Catalina and I are giving our minds a break from social networks and thinking about success and social value. What is success? What is social value? Do they go together? Should they? Peter Drucker tended to think success was maximizing shareholder value, and social value would result. It was a concept with good unifying utility and clarity. A friend of ours in the venture community was once fond of saying his favorite business model was a post box people sent money to.
Most entrepreneurs like to think they are doing more than just creating ways to transfer wealth, that they are doing something meaningful for others, not just taking their money. Many—if not most—profit-making businesses sell products and services that make life better in some way for their customers. Anyone who has taken a life-saving medication or paid for a useful service, for example, has left behind a profit for the provider and is thankful for the benefits received. It's not true of all businesses, of course, but most that make a profit also create something socially valuable to someone.
Remember, we think success is not an end goal. Success is a "second thing," one of those we mentioned in a November 2011 blog: "You can't get second things by putting them first. You can only get second things by putting first things first."[1] Whenever we have gone far enough in a conversation with an entrepreneur, we usually find most successful ones set out to do something they felt was worthwhile. Sure they wanted financial success, because financial success meant they had achieved what they really set out to do. And something has to pay the bills. But financial success was only a second thing. There was always this higher thing, a first thing. It always boils down to this—what do you want to achieve, and how will you achieve it? That first step, defining what's important personally, has to come from inside. It's the unifying theme of our entrepreneurs, from Phil McDonnell and Tom Brady, to John Justice and Christina Stoltz. "You can only get second things by putting first things first." In order to get what you want, you need to know what you really want. Most people want to succeed—not AND leave social value if they can, BUT succeed BY leaving social value behind. It's an important distinction.
There's this new buzzword, doing well by doing good. A synonym: social entrepreneurship. They often are treated as some important new category, as if for-profit enterprises are mercenary privateers (pirates) and nonprofits are business retards. Actually, there is no clean divide between entrepreneurship that seeks profits and entrepreneurship focused on the nonprofit world. In fact there is an almost seamless continuum from enterprises focused solely on wealth transfers (think: Bernie Madoff. Some would add investment bankers…) to those businesses who look to profit from goods and services, to nonprofit enterprises who think they are only doing charity. In between is everything from doing well by doing good to social enterprise.
Social enterprise uses market-driven business models to create social value and address critical social and environmental issues.[2] Barely a concept even twenty years ago, it's becoming an increasingly active space. A Lexis-Nexis search for social entrepreneur turned up 6 stories for 1991, 573 for 2001, and 1,682 for 2006.[3] There is no common definition, and there are many alternate terms—social ventures, nonprofit enterprise, social purpose business, venture development. Organizations span the range from for-profit to a new legal form—limited-profit organizations formed to simultaneously advance community benefit and earn a return for investors—to nonprofits which derive a substantial portion of their money from activities that look like a for-profit (think: Girl Scout Cookies). Even many traditional nonprofits living on grants, government contracts, and donations often strive to improve the effectiveness of their operations by adopting the execution and strategy practices of for-profit businesses.
Conceptually, the question of what enforces discipline and effectiveness is a complicated issue in social entrepreneurship. In the for-profit world winners are rewarded and the inefficient/ineffective are culled by market forces that judge on the basis of wealth creation (aka, financial profitability). These criteria provide a clear and useful means to assess not only success retrospectively, but also opportunity prospectively. Jim Collins wrote a nonprofit monograph to his mega-bestseller, Good to Great, in which he noted that, in contrast to the for-profit world, "the social sectors do not have rational capital markets that channel resources to those who deliver the best results… The whole purpose of the social sectors is to meet social objectives, human needs and national priorities that cannot be priced at a profit." [4]
Who is the entrepreneur? You are. Entrepreneurs want to find problems and solve them, needs and meet them, and that seems like a pretty fundamental point of departure in thinking about social value. Business model is a second thing; the success is the first thing.
Actually two Tuck Business School students, Christopher Halstedt and Brad Callow, did an independent study this past spring with Senior Associate Dean Bob Hansen and Gregg on exactly this topic. They set out to see if they could understand what exactly is social entrepreneurship and how it creates social value. Next week we'll look at some of their conclusions.
[1]Lewis, C. S. "First Things and Second Things,"God in the Dock. (Grand Rapids: Eerdmans, 1970): 278-281.
[2] Dees, J. Gregory, Jed Emerson and Peter Economy. Enterprising Nonprofits – A Toolkit for Social Entrepreneurs. (New York, NY: John Wiley & Sons, 2001): 4-5
[3] Bornstein, David. How to Change the World – Social Entrepreneurs and the Power of New Ideas. (New York, NY: Oxford University Press, 2007): 307.
[4] Collins, Jim. Good to Great and the Social Sectors, a monograph to accompany Good to Great. (Boulder, CO: Jim Collins, 2005). 19.


text:
So, regular readers know I am a bit obsessed with basketball. We had some wonderful friends in town last night and so I DVR'd the game and then set about trying to block out the outside world throughout dinner. I turned off my cell phone. I put my computer in an out of reach place. I had my girlfriend scout out the downstairs of the restaurant for TVs before I ventured down to the restroom (yes, she's wonderful. Also understanding.) And it worked….. until we were walking around outside and I looked into a bar and happened to see a bigscreen TV showing Billy Donovan with a net around his neck. A;LKDJF;LAKJF I about fainted on the sidewalk. Nooooooooo!! Anyway, congrats to the Gators, even if I didn't get to be surprised by the win. I still watched the game when I got home.
Anyway, the advice given in this blog has been mostly devoted to the art of the query letter, but really, that is putting the cart before the donkey. Aspiring writers agonize over query letters, they strive to make publishing contacts, they pour their time and energy into getting their book published. But actually, the absolute most crucial decision you can make as a writer happens before you take out your pen and write down, "Once upon a time in Borneo." The most important decision happens when you decide what you're going to write about.
Too many people assume that good writing is all you need, and believe what you write about isn't so important as how you write. Such thinking results not only in meandering 200,000 treatises on the peculiarity of our contemporary mores, but also in more mundane and unoriginal plots that aren't well thought through and thus, no matter how good the writing is, they are a tough prospect to sell. To put it short: You need a good idea.
When you're considering what to write about, you have to start with the assumption that everyone you're up against in the slush pile can write — it's your idea that will set you apart. This may seem like really obvious advice, but an unoriginal or not-good-enough book idea is the basis for approximately 90% of my rejections. In a story-saturated world where it seems like every original idea is already taken, really great story ideas are very rare and precious. I find it much more agonizing to reject someone with a really great idea where the writing isn't there than I do passing on a project with great writing where there isn't a solid enough idea. I think this is because it's so hard to find a great idea. They're as rare as an intelligent conversation on The Hills.
So what can you do? One way to test your idea before you start writing is to tell it to someone out loud. If, after a short description, someone genuinely, involuntarily responds, "Wow, that's a great idea," you're onto something. If you have to include the caveat, "Well, anyway, it sounds boring but really, it's all about the writing," you might want to add some monkeys to the plot.


text:
Lisgar Gardens are public gardens owned by Hornsby Council.
The Friends of Lisgar Gardens group was formed by Hornsby Council in 1993 to assist with promotion and protection of Lisgar Gardens.
Coming from all walks of life, Friends of Lisgar Gardens are a group of volunteers dedicated to assisting visitors for the enjoyment of our beloved gardens. We are at the gardens on Sundays to provide visitors with park information and assistance. We operate the inclinator to transport less-mobile visitors with access to the formal upper garden area. Check out upcoming community events that we organise annually and bring your friends and family. Come and say hello to our friendly volunteers.


text:
Notice: You are editing a prerequisite guide. Any changes you make will affect all 42 guides that include this step.
Translating step 7
Step 7
Insert a guitar pick into the gap between the LCD and rear case, near the top of the left side of the LCD.
Bend the pick slightly away from the iPad, just enough to spread the gap between the LCD and rear case.
Ваш вклад лицензируется под свободной лицензией Creative Commons.


text:
I'm using a Pfaff Creative 1471. I finally figured out the presser foot setting to use - it's surely not clear in the manual! :? I've scoured the internet sites and youtube for help with FMQ.
Basically they all pretty much say to practice every day for 2 years and you might eventually get the hang of it. I think you must also have to hold your tongue right, turn your fingers into rubber, and mindmeld with the machine.
My hardest things to conquer are regulating speed, stitch length, and a wonky bobbin thread that wants to peek thru the top.
Any hints or words of wisdom?


text:
The mortal intricacies of the surgical theatre and the laboratory work on which it depends are the centerpiece of Steven Soderbergh's TV series "The Knick," set in a downtown Manhattan hospital in 1900. Soderbergh (who does his own camera work) films it thrillingly, but his greatest inspirations unfold the details—intellectual and physical, analytical and gory—of medical practice. Closely bound to the show's unstinting view of scientific progress is the bureaucratic wrangling—in effect, the backstage business—that makes stunning medical productions possible. Clearly, Soderbergh and the screenwriters, Jack Amiel, Michael Begler, and Steven Katz, did their historical research. But, for a real-life, "Knick"-like account of the grim spectrum of sickness in turn-of-the-century New York that pierces the screen of dramatic artifice and shows the sort of visionary practicality that it took to change things, there's a very worthwhile read: "Fighting for Life," the 1939 autobiography by S. Josephine Baker (1873-1945), which was reissued last year by New York Review of Books Classics.
Baker was a doctor who started working as an inspector for the city's Department of Health in 1901, and soon rose to become the first head of the Department of Child Hygiene. But, following the chronological convention of autobiography, she buries the lede; it takes fifty-eight pages to get to the heart of the matter, a description of her first tour of duty in Hell's Kitchen:
I climbed stair after stair, knocked on door after door, met drunk after drunk, filthy mother after filthy mother and met dying baby after dying baby. … There was no dodging the hopelessness of it all. It was an appalling summer, too, with an average of fifteen hundred babies dying each week in the city; lean, miserable, wailing little souls carried off wholesale by dysentery.
The primary cause of this disease was unpasteurized milk: "the bulk of the milk supply that these babies were fed on was drawn from rusty cans and the milk was dotted with flies as well as full of bacteria." Her solution was simple: opening "baby milk stations" in storefronts throughout the city, which provided clean milk at prices below market rates. She coupled this with educational outreach, mainly to poor families in overcrowded neighborhoods, to overcome traditional resistance to pasteurized milk, which many considered less nutritious because it was "cooked." This, along with her other prescriptions for improved child care—including ventilation (overcoming traditional worries about drafts), lighter baby clothing, and a modified diet, helped to reduce the city's rate of baby deaths, she writes, "from fifteen hundred a week to around sixty a week."
Baker had an epiphany in the course of her work, and it gave rise to an enduring shift in the very nature of medicine: "The way to keep people from dying from disease, it struck me suddenly, was to keep them from falling ill." She suddenly conceived her mission as "teaching people how to stay well," or, in other words, "preventive medicine"—which, she wrote, "had hardly been born yet and had no portion in public-health work" when she took the helm of the newly founded Department of Child Hygiene, in 1908.
Baker's account of city life at the time of her entry into government work is appalling. Working in public schools soon after her Department of Health appointment, she found that four out of five children were infested with lice, contagious skin diseases were almost as endemic, and "one out of five, some 20 per cent, had trachoma, that highly infectious eye-disease which constitutes so serious a risk of blindness that the immigration authorities no longer allow any case of it to enter the country." She oversaw a program to delouse children, to treat skin disease, and to maintain separate classes for children afflicted with trachoma—and, in the process, began an over-all effort for in-school medical care for children that led to the now familiar institution of the school nurse.
Baker's early duties with the Department of Health involved such intrepid tasks as "invading Bowery lodging-houses, the ten-cents-a-night kind, for instance, to vaccinate the patrons against small-pox in the very early hours of the morning." Soon, she found herself—perhaps I'm burying the lede, too—helping another physician, George A. Soper, to solve the mystery of a typhoid epidemic among a seemingly unconnected group of well-to-do families. Of course, the culprit was a cook, Mary Mallon, now known as Typhoid Mary. The story of her capture is terrifically detailed and cinematic: "Mary was on the lookout and peered out, a long kitchen fork in her hand like a rapier. As she lunged at me with the fork, I stepped back, recoiled on the policeman and so confused matters that, by the time we got through the door, Mary had disappeared." What followed was a search that implicated her fellow domestics (whose closing of ranks in her defense fascinated Baker) and a chase that involved slapstick elements.
These adventures were a far cry from Baker's seemingly idyllic childhood in Poughkeepsie; her father was a prominent attorney, her mother was one of Vassar's first graduates, and her tales of romantic outdoorsy exuberance, with clambakes and boat racing, ice skating and "ice-yachting," cheerful excursions and teeming family gatherings, are reminiscent of Orson Welles's "The Magnificent Ambersons." She also relates anecdotes replete with strange, resonant details, such as a story about one Dr. Jackson, who "made, and had his patients eat, what I believe was the first prepared breakfast food: a really delicious concoction called 'granula' " (i.e. granola).
But Baker's father died when she was sixteen and she became, by default, the sole means of her family's long-term support; renouncing her long-planned matriculation at Vassar, she went to New York to study medicine at the Women's Medical College of the New York Infirmary, at Stuyvesant Square and East Fifteenth Street (just four blocks north of Knickerbocker Hospital). Graduating in 1898, she became an "interne" at New England Hospital, in Boston, a city that also had pockets of horrific poverty. Her description of an emergency delivery at which she assisted in a fetid tenement features the harrowing comedy, sincere compassion, and cold clinical detachment that tinges much of her writing.
When she returned to New York, she opened an office on the Upper West Side: "In those days, Amsterdam Avenue … was filled with squatters' shacks made of hammered-out tin cans and waste lumber, inhabited by ne'er-do-wells and swarming with goats." The early years of medical practice were, as she had been warned, lean; she applied for work with the Department of Health not out of any sense of public-spirited mission but because the pay was thirty dollars a month, or, as she writes, "A dollar a day: about double my first year's rate of income."
Baker's book is studded with sharply ironic reflections on the wider implications of the medical world. She writes of her preference for dealing with the backroom wheeler-dealers of the Tammany Hall machine rather than with "reformers": good-government advocates subjected her projects to extended study and careful cost accounting, whereas party hacks cut through red tape and got things done. "At bottom they were thoroughly corrupt and cynical, a sort of government cancer," she writes, but they nonetheless saw the interest (and self-interest) in helping the poor by means of programs that they financed shadily—"this baffling mixture of official incompetence explained to me, in part at least, Tammany's hold on the people: large spending and innate humanity."
She spent decades crusading against child labor, proposing in vain a constitutional amendment against it; at the time of her writing, in the late thirties, she found the practice happily less prevalent: "We have made some progress, due largely I think to the adult need of the jobs that children used to get with little or no trouble." If children had the Depression to thank for their improved condition, they could also thank the Great War, which she called "a backhanded break for children" due less, she thought, to their status as "the hope of the nation" than as "future supplies of cannon fodder." She also writes of a political-hack supervisor who, during the war, told her, "By the way, I am changing the name of German measles. Hereafter it will be known as 'Liberty measles.' " (She adds, "And it did bear that extraordinary title for the duration of the war.")
Baker discusses her visit to the Soviet Union in the early nineteen-thirties—which she undertook with mitigated enthusiasm and a clear recognition of the chill of purges and the weight of dogma. (In a ward filled with silent babies, a nurse told her, "Why should a Soviet baby cry? There is nothing to cry about.") Yet her observations there led to her advocacy of "state medicine," although with "safeguards and concessions to our democratic ideal," as, for example, to insure the choice of doctors, as well as her hint at an endorsement of legal abortion.
And she was a leading campaigner for women's suffrage, for which she gave speeches and even met with President Woodrow Wilson as part of a compact delegation seeking (and winning) his support. Yet she called the passage of the Nineteenth Amendment, in 1920, "at once a great victory and a great deprivation. When the enemy was routed, the woman's suffrage army was disbanded and we lost all that sense of solidarity and comradeship." She described the trouble she faced, early in her career, in getting men to accept a female boss, and decried the enduring obstacles that stood in the way of women's full participation in public life.
I hold no brief for women as women. There are good and bad in their ranks. … During the suffrage days I had no great illusion about my sex; I wanted the vote as a matter of common justice. But I still believe that women have something to offer this sick world that men either do not have or have not offered.
As for her private life, Baker was as frank as could be expected for a popular author of her time. She wrote of her medical-school friend Dr. Florence M. Laighton, "with whom I lived and practiced for many years." ("Dr. Laighton and I had made enough money to take a house for ourselves, a four-story affair which had been built for Rose Coghlan, the great actress, on a side street off Central Park.") In her later years (as Helen Epstein writes in her introduction to the book), Baker shared a house in Princeton with the screenwriter and novelist Ida Wylie (whom Baker mentions in passing) and the scientist Louise Pearce.
There are no female doctors in "The Knick"—at least, not in the first seven episodes—and no horrific squalor and endemic disease akin to what Baker observed and combated. The series features a health inspector who makes his rounds, one who is perhaps analogous to Dr. Soper, but there's no Dr. Baker at his side (though another woman at his side is an important enough character on her own). But there's a second season coming.


text:
|Computes the maximum value of a two-player non-local game
|Other toolboxes required
|Related functions
| BCSGameValue
|Function category
|Nonlocality and Bell inequalities
|Usable within CVX?
NonlocalGameValue is a function that computes the maximum possible value of a given non-local game under either classical mechanics, quantum mechanics, or general no-signalling theories. In the classical and non-signalling cases, an exact value is computed, whereas the value computed in the quantum case is only an upper bound (found using the NPA hierarchy).
- NGVAL = NonlocalGameValue(P,V)
- NGVAL = NonlocalGameValue(P,V,MTYPE)
- NGVAL = NonlocalGameValue(P,V,MTYPE,K)
Argument descriptions
- P: A probability matrix whose $(x,y)$-entry gives the probability that the referee asks Alice question $x$ and Bob question $y$.
- V: A 4-D array whose $(a,b,x,y)$-entry gives the value awarded to Alice and Bob if they reply with answers $(a,b)$ to questions $(x,y)$.
- MTYPE (optional, default 'classical'): A string indicating which type of theory should be used when computing the maximum value of the non-local game. Must be one of 'classical', 'quantum', or 'nosignal'. If MTYPE = 'quantum' then only an upper bound on the non-local game is computed, not necessarily the best upper bound (see the argument K below).
- K (optional, default 1): If MTYPE = 'quantum' then this is a non-negative integer indicating what level of the NPA hierarchy should be used when bounding the value of the non-local game. Higher values of K give better bounds, but require more memory and time. Alternatively, K can be a string of a form like '1+ab+aab', which indicates that an intermediate level of the hierarchy should be used, where this example uses all products of 1 measurement, all products of one Alice and one Bob measurement, and all products of two Alice and one Bob measurement. Use plus signs to separate the different categories of products, as above. The first character of this string should always be a number, indicating the base level to use. If MTYPE is anything other than 'quantum' then K has no effect.
The CHSH inequality
One formulation of the CHSH inequality[1] is as follows:
- A referee asks Alice a question $x \in \{0,1\}$ and Bob a question $y \in \{0,1\}$.
- Alice and Bob then reply with answers $a \in \{0,1\}$ and $b \in \{0,1\}$ respectively.
- Alice and Bob win if and only if $a \oplus b = xy$.
The optimal probability with which Alice and Bob can win this game in classical, quantum, and no-signalling theories are as follows:
>> d = 2; >> p = ones(d,d)/d^2; >> V = zeros(d,d,d,d); >> for a = 1:d for b = 1:d for x = 1:d for y = 1:d if(mod(a+b+x*y,d)==0) V(a,b,x,y) = 1; end end end end end >> NonlocalGameValue(p,V,'classical') ans = 0.7500 >> NonlocalGameValue(p,V,'quantum',1) ans = 0.8536 >> NonlocalGameValue(p,V,'nosignal') ans = 1.0000
The CHSH-d inequality
A generalization of the CHSH inequality to higher dimensions is exactly as above, except each of $a,b,x,y$ are taken from the set $\{0,1,\ldots,d-1\}$.[2] The following code computes the values of the CHSH-3 game:
>> d = 3; >> p = ones(d,d)/d^2; >> V = zeros(d,d,d,d); >> for a = 1:d for b = 1:d for x = 1:d for y = 1:d if(mod(a+b+x*y,d)==0) V(a,b,x,y) = 1; end end end end end >> NonlocalGameValue(p,V,'classical') ans = 0.6667 >> NonlocalGameValue(p,V,'quantum',1) ans = 0.7182 >> NonlocalGameValue(p,V,'quantum',2) ans = 0.7182 >> NonlocalGameValue(p,V,'quantum','2+aab') ans = 0.7124 >> NonlocalGameValue(p,V,'nosignal') ans = 1.0000
The Fortnow-Feige-Lovász game
The Fortnow-Feige-Lovász (FFL) game[3][4] is well-known example of a non-local game for which perfect parallel repetition does not hold (i.e., quantum players playing two copies of the game in parallel can do better than they can by playing the games in succession).
The game has binary inputs and outputs, and is defined by the rule that the referee asks Alice and Bob the question pair $(x,y) = (0,0)$, $(0,1)$, or $(1,0)$ with probability $1/3$ each, and Alice and Bob win if and only if their answers satisfy $x \vee a \neq y \vee b$, where $\vee$ denotes the bitwise OR operation.
It is known that both the classical value and quantum value of this game equal $2/3$, which we can verify as follows:
>> p = [1 1;1 0]/3; >> V = zeros(2,2,2,2); >> for a = 1:2 for b = 1:2 for x = 1:2 for y = 1:2 if(max(x,a) ~= max(y,b)) V(a,b,x,y) = 1; end end end end end >> NonlocalGameValue(p,V,'classical') ans = 0.6667 >> NonlocalGameValue(p,V,'quantum',1) ans = 0.6667
Parallel repetition
In fact, we can even compute the classical and quantum values of two copies of the FFL game being run in parallel: we simply specify the REPT input argument to be 2:
>> NonlocalGameValue(p,V,'classical',1,2) ans = 0.6667 >> NonlocalGameValue(p,V,'quantum',1,2) ans = 0.6667
Indeed, the fact that both of these values also equal $2/3$ is a known fact [5]. Note that in the command NonlocalGameValue(p,V,'classical',1,2), the "1" that is provided as the value of K does not do anything: it is simply provided as a placeholder so that we can set REPT = 2 in the next input argument (e.g., we could have just as well entered the command NonlocalGameValue(p,V,'classical',9873,2), and the same calculation would have been carried out).
Source code
Click on "expand" to the right to view the MATLAB source code for this function.
%% NONLOCALGAMEVALUE Computes the maximum value of a two-player non-local game
% This function has two required input arguments:
% P: a matrix whose (x,y)-entry is the probability that the referee
% asks Alice question x and Bob question y
% V: a 4-D array whose (a,b,x,y)-entry is the value given to Alice and
% Bob when they provide answers a and b respectively to questions x
% and y.
% NGVAL = NonlocalGameValue(P,V) is the maximum value that the specified
% non-local game can take on in classical mechanics. For the maximum
% quantum or no-signalling value, see the optional arguments described
% below.
% This function has three optional input arguments:
% MTYPE (default 'classical'): one of 'classical', 'quantum', or
% 'nosignal', indicating what type of nonlocal game value should be
% computed. IMPORTANT NOTE: if MTYPE='quantum' then only an upper
% bound on the non-local game value is computed, not its exact value
% (see the argument K below).
% K (default 1): if MYTPE='quantum', then K is a non-negative integer
% or string indicating what level of the NPA hierarchy to use to
% bound the non-local game (higher values give better bounds, but
% require more computation time). See the NPAHierarchy function for
% details. If MTYPE is anything else, then K is simply ignored.
% REPT (default 1): the number of times that the non-local game should
% be played in parallel (i.e., the number of repetitions of the
% game).
% NGVAL = NonlocalGameValue(P,V,MTYPE,K,REPT) is the maximum value that
% the specified non-local game can take on in the setting (classical,
% quantum or no-signalling) specified by MTYPE.
% URL: http://www.qetlab.com/NonlocalGameValue
% requires: CVX (http://cvxr.com/cvx/), NPAHierarchy.m, opt_args.m,
% update_odometer.m
% author: Nathaniel Johnston (email@example.com)
% package: QETLAB
% last updated: July 10, 2015
function ngval = NonlocalGameValue(p,V,varargin)
% set optional argument defaults: MTYPE='classical', K=1, REPT=1
[mtype,k,rept] = opt_args({ 'classical', 1, 1 },varargin{:});
% Get some basic values.
[ma,mb] = size(p);
oa = size(V,1);
ob = size(V,2);
% Are we playing the game multiple times? If so, adjust p and V
% accordingly.
if(rept > 1)
% Create the new probability array.
p = Tensor(p,rept);
% Create the new winning output array (this is more complicated
% since MATLAB doesn't have any built-in functions for tensoring
% together 4D arrays).
V2 = zeros(oa^rept,ob^rept,ma^rept,mb^rept);
i_ind = zeros(1,rept);
j_ind = zeros(1,rept);
for i = 1:ma^rept
for j = 1:mb^rept
for l = rept:-1:1
to_tensor{l} = V(:,:,i_ind(l)+1,j_ind(l)+1);
V2(:,:,i,j) = Tensor(to_tensor);
j_ind = update_odometer(j_ind,mb*ones(1,rept));
i_ind = update_odometer(i_ind,ma*ones(1,rept));
% Update some computed values.
ma = ma^rept;
mb = mb^rept;
oa = oa^rept;
ob = ob^rept;
% The no-signalling maximum is just implemented by taking the zero-th
% level of the NPA (quantum) hierarchy.
mtype = 'quantum';
k = 0;
% Compute the maximum value of the non-local game, depending on which
% type of maximum was requested.
cvx_begin quiet
variable q(oa,ob,ma,mb);
maximize sum(sum(p.*squeeze(sum(sum(V.*q,1),2))))
subject to
NPAHierarchy(q,k) == 1;
ngval = cvx_optval;
% Deal with error messages.
warning('NonlocalGameValue:NumericalProblems','Minor numerical problems encountered by CVX. Consider adjusting the tolerance level TOL and re-running the script.');
warning('NonlocalGameValue:NumericalProblems','Minor numerical problems encountered by CVX. Consider adjusting the tolerance level TOL and re-running the script.');
elseif(strcmpi(cvx_status,'Unbounded') || strcmpi(cvx_status,'Inaccurate/Unbounded') || strcmpi(cvx_status,'Failed'))
error('NonlocalGameValue:NumericalProblems',strcat('Numerical problems encountered (CVX status: ',cvx_status,'). Please try adjusting the tolerance level TOL.'));
% Compute the classical maximum value just by brute-forcing over
% all possibilities.
ngval = -Inf;
a_ind = zeros(1,ma);
b_ind = zeros(1,mb);
a_ind(ma) = oa-2;
b_ind(mb) = ob-2;
p = permute(repmat(p,[1,1,oa,ob]),[3,4,1,2]);
ab_prob = zeros(oa,ob,ma,mb);
for i = 1:oa^ma
for j = 1:ob^mb
for x = 1:ma
for y = 1:mb
ab_prob(:,:,x,y) = zeros(oa,ob);
ab_prob(a_ind(x)+1,b_ind(y)+1,x,y) = 1;
tgval = sum(sum(sum(sum(p.*V.*ab_prob))));
if(tgval >= ngval - 0.000001)
ngval = max(ngval, sum(sum(sum(sum(p.*V.*ab_prob)))));
b_ind = update_odometer(b_ind, ob*ones(1,mb));
a_ind = update_odometer(a_ind, oa*ones(1,ma));
error('NonlocalGameValue:InvalidMTYPE','MTYPE must be one of ''classical'', ''quantum'', or ''nosignal''.');
In practice, K probably can't be any larger than 4 when MTYPE = 'quantum', due to memory and time restrictions.
- ↑ J.F. Clauser, M.A. Horne, A. Shimony, R.A. Holt. Proposed experiment to test local hidden-variable theories. Phys. Rev. Lett., 23(15):880–884, 1969.
- ↑ M. Howard. Maximum nonlocality and minimum uncertainty using magic states. E-print: arXiv:arXiv:1501.05319 [quant-ph], 2015.
- ↑ U. Feige, L. Lovász, In Proceedings of the 24th ACM STOC, pages 733-744, 1992.
- ↑ L. Fortnow, PhD thesis, Massachusetts Institute of Technology, Technical Report MIT/LCS/TR-447, May 1989.
- ↑ R. Cleve, W. Slofstra, F. Unger, and S. Upadhyay. Perfect parallel repetition theorem for quantum XOR proof systems. Computational Complexity, 17:282–299, 2008. E-print: arXiv:quant-ph/0608146


text:
- Home
- About
- Your School
- Community Campus
- Children's Centre
- For Parents
- Latest News
- Contact
At Elizabeth Grove Primary we strive to promote the benefits of living a healthy and active lifestyle, in and out of school. Students in all year levels actively participate in at least one specialist lesson a week. The specialist program provides students with the opportunity to develop, refine and practice skills that are fundamental to their physical development and participation in physical activity and sports.
In the primary setting we aim to provide many opportunities and experiences for our students to explore their interests and skills in physical activities. As students get older, they are introduced to a wide variety of sports to try and may also have the opportunity to compete in inter school carnivals.
The PE program is centered around the core school value of 'we try your personal best' and ensuring a 'have a go' attitude. The program also places a huge emphasis on developing team work and social skills through peer interaction.
It is great to see the students having fun with their peers and trying new things in PE!
External School Review Report 2016
Site Improvement Plan 2015-2017


text:
Whales and Fjord of Saguenay
As the Charlevoix's eastern most municipality before Tadoussac, Baie-Sainte-Catherine sits at the junction of the Saguenay and St. Lawrence Rivers. Between May and October, countless whale-watching cruise ships moored at Baie-Sainte-Catherine Pier offer visitors a chance to observe marine mammals out on the water. In the Baie-Sainte-Catherine sector, blue whales, humback whales, fin whales and belugas can all be admired as they feed nearby. This exceptional environment is teeming with rich food for marine mammals, making it a privileged destination for an unparalleled experience with nature!


text:
Cool Site of the Day – 9/22/11: TextFixer.com
Today's Cool Site of the Day is TextFixer.com
Online tools and resources for webmasters and web developers. Easily change text and html, remove line Breaks, capitalize sentences, convert text to basic html and other common tasks.
Go see it and rate it TODAY (Note: if you're seeing this on a date later than the featured date, visit the Still Cool Archive)


text:
Infection by Mycobacterium tuberculosis (MTB) remains a major public health problem in the world. In this respect, tuberculosis (TB) is the second cause of death after human immunodeficiency virus (HIV) infection and is the most common cause of death of people infected with HIV (Corbett et al. 2003, Blanc & Martinez 2007).
Most MTB-infected individuals remain asymptomatic, with a small proportion of them eventually progressing to active TB disease. Therefore, they may become a reservoir of Mycobacterium and this may constitute an obstacle to its eradication. The most common manifestation of TB is a chronic pulmonary disease and immunocompromised individuals are the most prone to developing symptomatic disease (Girardi et al. 2000, Stewart et al. 2003).
The diagnosis of latent MTB infection remains a challenge. The tuberculin skin test (TST), also known as the purified protein derivative (PPD) skin test, is still largely employed as a diagnostic tool, but it has shown low specificity, as it often displays antigenic cross-reactivity with unrelated microorganisms (Dinnes et al. 2007). The tests that measure interferon (IFN)-γ production, IFN-γ release assays (IGRA), were developed to detect latent TB and are based upon the detection of IFN-γ produced specifically from peptides identified during infection with MTB; they are considered to be more specific than TST for the diagnosis of Mycobacterium infection. One of these tests, the enzyme-linked immunospot (ELISPOT) assay, was shown to have a better diagnostic performance when compared with TST (Ewer et al. 2003, Fietta et al. 2003, Brock et al. 2004). The ELISPOT assay is closely correlated with the exposure of the individual to Mycobacterium (Ewer et al. 2003) and shows less indeterminate results than TST tests (Dogra et al. 2007).
A peptide-based IGRA test could offer several advantages, including the precise knowledge of the antigen specificity. However, such peptides should be widely recognised by the population to be tested. Until recently, the available tools for searching immunodominant epitopes was the direct testing of substantial numbers of overlapping peptides or peptide libraries. The identification of major histocompatibility complex-binding motifs allowed the prediction of potential T-cell epitopes (Rammensee 1995) and such motifs were found to cluster in certain protein regions (Meister et al. 1995). The TEPITOPE algorithm predicts binding to 25 distinct human leukocyte antigen (HLA)-DR molecules based on quantitative matrices established from HLA-DR binding assays (Sturniolo et al. 1999, Bian et al. 2003, Iwai et al. 2003, Fonseca et al. 2004, 2006, Damico et al. 2005). This advance lead to the selection of sequences enriched for high affinity-binding peptides, those with the highest chance of eliciting effective T-cell responses against immunogens (Schroers et al. 2002). Additionally, TEPITOPE also allows for the detection of sequences predicted to bind to several HLA-DR molecules simultaneously, opening the possibility of selecting promiscuous T-cell epitopes. Another advantage of the peptide-based IGRA test is the ability to test individual peptides, allowing for the analysis of peptide-specific T cell responses as well as peptide pools.
Therefore, to identify the frequently recognised immunodominant epitopes of three immunogenic proteins of MTB, we used the TEPITOPE algorithm to screen GroEL-2 (Shinnick 1987, Fleischmann et al. 2002), phosphate-binding protein 1 precursor (PBP-1) (Andersen & Hansen 1989) and 19 kDa antigen (Ashbridge et al. 1989), which are proteins that were previously found to elicit potentially strong immunological responses (Tanghe et al. 1999, Lewthwaite et al. 2001, Mendelson et al. 2005, Wilkinson et al. 2009), for multiple HLA-DR binding sequences, in a group of healthy individuals. Synthetic peptides encoding such potential CD4+ T cell epitopes were used in IFN-γ ELISPOT assays with peripheral blood mononuclear cells (PBMCs) of TST-positive and TST-negative Brazilian healthy subjects.
Subjects - The sample comprised 32 Brazilian healthy volunteers (donors) selected from students and workers from the Advanced Laboratory of Public Health, Oswaldo Cruz Foundation (Fiocruz), Salvador, state of Bahia, Brazil, and the Immunology Laboratory, Heart Institute, University of São Paulo (USP), São Paulo, state of São Paulo, Brazil. All donors received Bacille Calmette-Guérin (BCG) vaccination during childhood. The mean age of the 32 donors was 32 ± 9 years. They were divided into two groups according to the TST response: latent MTB infection (16 subjects, TST-positive) and uninfected controls (16 subjects, TST-negative), with a mean age of 35 ± 11 years (TST-positive) or 30 ± 7 years (TST-negative). The TST was performed according to the Mantoux method with PPD, following the manufacturer's instructions (Statens Serum Institute, Denmark). TST was considered positive when the induration was ≥ 10 mm after 48 h of PPD application. All of the individuals gave their written informed consent to participate in this study, which was approved by the Institutional Review Boards of the School of Medicine, USP (protocol 250/04) and Fiocruz (protocol 51/2004).
Peptide selection - Sequences of three important antigens expressed by MTB were used: GroEL2 protein, accession P9WPE6.1 (Fleischmann et al. 2002), PBP-1, accession P9WGU0.1 (Andersen & Hansen 1989) and 19 kDa antigen, accession S02753 (Ashbridge et al. 1989). These sequences were screened by TEPITOPE and we predicted seven epitopes that were used in the ELISPOT assay. The seven peptides were predicted to bind to at least 12 out of the 25 HLA-DR molecules in the TEPITOPE matrix, as previously described (Bian et al. 2003). They correspond to an inner nonamer core selected as the HLA-binding motif with flanking amino acids added when possible (e.g., conserved flanking sequences) at either or both the N and C-terminal ends, to increase the efficiency of in vitro peptide presentation to CD4+ T cells (Bian et al. 2003, Fonseca et al. 2006).
Peptide synthesis - Peptides of the MTB proteins were synthesised by solid phase technology using 9-fluorenylmethoxycarbonyl strategy, with the C-terminal carboxyl group in amide form. Peptide purity and quality were assessed by reverse-phase high performance liquid chromatography and mass spectrometry, as described elsewhere (Atherton & Sheppard 1989). The peptides were dissolved in dimethyl sulfoxide (DMSO) for stock solutions of 25 mg/mL.
PBMC separation - PBMC suspensions were prepared from 50 mL heparinised venous blood by density gradient centrifugation using Ficoll-Hypaque, 1.077 g/L (Pharmacia, Sweden). The cells were washed twice with phosphate-buffered saline (PBS) (Gibco, UK) and were kept frozen at -196ºC in liquid nitrogen in foetal calf serum (FCS) containing 10% DMSO (Merck, Germany) until testing. After thawing, the PBMCs were suspended in RPMI-1640 (Gibco), supplemented with 200 mM glutamine, 100 U/mL penicillin, 100 U/mL streptomycin and 10% FCS, 100 mM non-essential amino acids and 100 mM pyruvate.
IFN-γ ELISPOT assays - The IFN-γ ELISPOT assay was performed as described previously (Sun et al. 2003, Fonseca et al. 2005, Zhang et al. 2009, Xie et al. 2010). Briefly, cryopreserved PBMCs (105 cells/well) were incubated with 5 μM of each peptide on a 96-well MultiScreen ELISPOT plate (Multiscreen MAIPS4510; Millipore, USA) previously coated with 50 μL/well of capture anti-human IFN-γ monoclonal antibody (mAb) diluted 1/1,000 (IgG1/B-B1; Diaclone, France) in PBS (1 μL/mL of mAb) at 4ºC overnight. The plates were washed three times with PBS. The remaining peptide binding sites were blocked with 100 μL RPMI/10% FCS for 2 h at 37ºC. The medium was removed just before the addition of cell suspensions (100 μL) and stimulating agents (100 μL). The MTB peptides (5 μM) were added to each well of the plates. The plates were incubated for 20 h at 37ºC in 5% CO2. PBMCs incubated with 0.5 μg/mL phytohemagglutinin (Sigma, France) or RPMI/10% FCS served as the positive and negative controls, respectively. At the end of the incubation, the cells were removed from the ELISPOT plates by washing nine times: three times with PBS, three times with PBS containing 0.05% Tween-20 (Sigma) and three times again with PBS. Spots were detected after the addition of the second biotinylated anti-human IFN-γ mAb (B-G1; Diaclone) (100 μL/well, 4 h, 37ºC in 5% CO2), diluted 1/500 in PBS-bovine serum albumin (PBS-BSA) (Gibco) (1 μL/500 μL of biotinylated antibody). The plates were washed three times with PBS, followed by streptavidin-alkaline phosphatase conjugate (Amersham, France) (100 μL/well, 1 h, 37ºC in 5% CO2) diluted 1/1000 in PBS-BSA (1 μL/mL of streptavidin-alkaline phosphatase conjugate), washed three times with PBS and incubated with 50 μL/well of chromogen substrates 5-bromo-4-chloro-3-indolyl-phosphate toluidine and 4-nitroblue tetrazolium (Sigma), which were incubated at room temperature (25ºC) until the appearance of violet spots (~ 30 min). The plates were washed with tap water and dried overnight. Antigen-specific T cells, expressed as spot forming cells (SFC)/106 PBMCs frequencies, were measured using an automated stereomicroscope (KS ELISPOT; Carls Zeiss, Germany). The SFC number was calculated after subtracting the negative control values (wells with cells in the absence of peptide) from the same subject. The positivity cut-off was ≥ 30 IFN-γ SFC/106 PBMCs, which was above the mean ± 3 standard deviation of the highest response found among all uninfected control subjects to any peptide (data not shown). The magnitude of response to each given peptide or the sum of the SFC of the total peptides was calculated as the SFC/106 PBMCs of peptides with responses above the positivity cut-off.
Statistical analysis - Statistical analysis was performed using the GraphPad Prism package v.3.0. Comparisons of the number of IFN-γ SFC/106 PBMCs between the clinical groups were performed with a non-parametric one-way ANOVA, Kruskal-Wallis and Dunn's Test. The Mann-Whitney U test was used to calculate the differences between the groups. Values of p < 0.05 were considered significant.
Three MTB antigenic proteins, GroEL2, PBP-1 and 19 kDa, were scanned with the TEPITOPE algorithm at a 3% threshold. Seven peptide sequences predicted to bind to multiple HLA-DR molecules were synthesised (Table I).
Next, we tested if the IFN-γ response to the seven peptides could discriminate between TST-positive and TST-negative healthy donors. The mean size (± standard deviation) of PPD induration detected for TST-negative individuals was 0.71 ± 2.02 mm and for TST-positive individuals was 11.14 ± 4.07 mm. PBMCs from the 16 TST-positive and 16 TST-negative individuals were tested in the presence of each peptide for an IFN-γ ELISPOT assay. The T cell responses are shown in Table II. The frequency of peptide recognition by the TST-positive group was significantly higher than the TST-negative group. Eighty-eight percent (14 out of 16 donors) of TST-positive donors recognised at least one peptide and 31% (5 out of 16 donors) had responses to three or more peptides, while in the TST-negative group, 31% (5 out of 16 donors) responded to any peptides and only 12% (2 out of 16 donors) responded to three or more peptides (p = 0.002) (Fig. 1).
Each of the selected peptides induced IFN-γ production by PBMCs from at least 31% of the TST-positive donors. The frequency of responders to individual peptides ranged from 31% to PBP-1 (118-133), PBP-1 (352-371) and 19 kDa (127-141) to 56% to GroEL2 (215-229) (Fig. 2). In contrast, among TST-negative donors, there was no response to GroEL2 (463-477) peptide and the most frequently recognised peptides were PBP-1 (351-365) and PBP-1 (352-371), with 19% of responders.
The magnitude of responses to the peptides (sum of IFN-γ SFC of all peptides with positive responses) was higher in the TST-positive group than in the TST-negative group (Fig. 3). The total number of IFN-γ SFC in response to MTB peptides was 182 ± 230 SFC/106 PBMCs among the TST-positive donors, compared to 36 ± 62 SFC/106 PBMCs in the TST-negative donors (p = 0.007). The magnitude of the responses per individual ranged from 0-725 SFC/106 PBMCs among the TST-positive individuals and 0-170 SFCs/106 PBMCs among the TST-negative individuals (Table II).
The PBP-1 (351-365) MTB peptide induced the highest magnitude of response, 627 SFC/106 PBMCs, followed by PBP-1 (352-371), with 446 SFC/106 PBMCs (Fig. 3). In the TST-negative group, the highest magnitude of response was to PBP-1 (352-371), with 185 SFC/106 PBMCs. In addition, a response to GroEL2 (463-477) was observed only in the TST-positive group (p = 0.02).
Taking into consideration that all 32 healthy donors were subjected to BCG vaccination, the combination of TST and positivity at the IFN-γ ELISPOT test raised the overall positivity value from 50% (16/32) to 59% (19/32) for recognition of MTB antigens.
Our results suggest that the peptides predicted by TEPITOPE are able to identify a significant number of individuals with latent MTB infection. Moreover, in our study, the use of these peptides allowed us to identify individuals with latent MTB infection not tracked by the TST test.
The TEPITOPE is an algorithm that uses a matrix that predicts the binding of 25 HLA-DR molecules. This allows the identification of epitopes with high binding affinity and the ability to generate a strong T cell response. The use of this algorithm can lead to the identification of a greater number of epitopes, which would display a higher sensitivity and specificity for detecting MTB, as reported elsewhere (Zhang et al. 2010).
The two methods used in this study to assess latent MTB infection, the TST and the IFN-γ ELISPOT, showed similar results in 88% of the evaluated individuals who were TST-positive. These findings are similar to the published data, in which there is a higher correlation of IGRA tests and TB when compared to TST and TB (Bartalesi et al. 2009, Girardi et al. 2009, Redelman-Sidi & Sepkowitz 2013). Furthermore, it was possible to identify TST-negative individuals (31%) who responded to peptides predicted by TEPITOPE. In this respect, Ewer et al. (2003) reported that ELISPOT offers a more accurate approach than TST for the identification of individuals who have latent TB infection and could improve TB control by more precise targeting of preventive treatment. However, possible antigenic cross-reactions or non-specific responses cannot be excluded and should be addressed. The advantage of using the IGRA with seven promiscuous peptides is that would ensure larger number of responder individuals independent of HLA class II and also a greater range or a greater number of recognised peptides.
To date, no fully effective methodology is available that can unequivocally differentiate individuals who actually have latent MTB infection from those who were BCG vaccinated or even those that have active MTB infection. The most widely and currently used test for the screening of latent MTB infection remains the TST because it is considered a low cost point-of-care-test (Ewer et al. 2003, Diel et al. 2007, Soborg et al. 2009). Therefore, it remains the method of choice for screening for latent MTB infection, primarily due to a better cost/benefit ratio when compared to tests based on IGRA (Lewinsohn et al. 2010).
Richeldi et al. (2009) report that immunocompromised persons infected with MTB have a high occurrence of false-negative results in the TST and, in such cases, they recommend to tailor the application of IGRA assays for latent MTB infection in different high-risk groups and advise caution in their use in immunosuppressed patients.
The results of the TST may show false positive results in individuals previously immunised with BCG or because the population of the study has high rates of exposure to MTB (Soborg et al. 2009). Another relevant aspect is that 70-80% of individuals with pulmonary TB have a diameter of the induration greater than 10 mm by TST and this value is reduced in individuals co-infected with HIV-1 (Idh et al. 2010). This combination of novel MTB CD4+ T-cell epitopes should be tested in a larger cohort of individuals with latent TB to confirm its potential to discriminate latent MTB infection from no TB infection and may be included in ELISPOT-based IFN-γ response assays to identify individuals with such conditions.
Andersen AB, Hansen EB 1989. Structure and mapping of antigenic domains of protein antigen b, a 38,000-molecular-weight protein of Mycobacterium tuberculosis. Infect Immun 57: 2481-2488.
Ashbridge KR, Booth RJ, Watson JD, Lathigra RB 1989. Nucleotide sequence of the 19 kDa antigen gene from Mycobacterium tuberculosis. Nucl Acids Res 17: 1249.
Atherton E, Sheppard RC 1989. Solid phase peptide synthesis: a practical approach, Oxford University Press, Cary, 216 pp.
Bartalesi F, Vicidomini S, Goletti D, Fiorelli C, Fiori G, Melchiorre D, Tortoli E, Mantella A, Benucci M, Girardi E, Cerinic MM, Bartoloni A 2009. QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases. Eur Respir J 33: 586-593.
Bian H, Reidhaar-Olson JF, Hammer J 2003. The use of bioinformatics for identifying class II-restricted T-cell epitopes. Methods 29: 299-309.
Blanc L, Martinez L 2007. The international TB control targets. Bull World Health Organ 85: 326.
Brock I, Weldingh K, Lillebaek T, Follmann F, Andersen P 2004. Comparison of tuberculin skin test and new specific blood test in tuberculosis contacts. Am J Respir Crit Care Med 170: 65-69.
Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, Dye C 2003. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 163: 1009-1021.
Damico FM, Cunha-Neto E, Goldberg AC, Iwai LK, Marin ML, Hammer J, Kalil J, Yamamoto JH 2005. T-cell recognition and cytokine profile induced by melanocyte epitopes in patients with HLA-DRB1*0405-positive and negative Vogt-Koyanagi-Harada uveitis. Invest Ophtalmol Vis Sci 46: 2465-2471.
Diel R, Nienhaus A, Loddenkemper R 2007. Cost-effectiveness of interferon-gamma release assay screening for latent tuberculosis infection treatment in Germany. Chest 131: 1424-1434.
Dinnes J, Deeks J, Kunst H, Gibson A, Cummins E, Waugh N, Drobniewski F, Lalvani A 2007. A systematic review of rapid diagnostic tests for the detection of tuberculosis infection. Health Technol Assess 11: 1-196.
Dogra S, Narang P, Mendiratta DK, Chaturvedi P, Reingold AL, Colford Jr JM, Riley LW, Pai M 2007. Comparison of a whole blood interferon-gamma assay with tuberculin skin testing for the detection of tuberculosis infection in hospitalized children in rural India. J Infect 54: 267-276.
Ewer K, Deeks J, Alvarez L, Bryant G, Waller S, Andersen P, Monk P, Lalvani A 2003. Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet 361: 1168-1173.
Fietta A, Meloni F, Cascina A, Morosini M, Marena C, Troupioti P, Mangiarotti P, Casali L 2003. Comparison of a whole-blood interferon-gamma assay and tuberculin skin testing in patients with active tuberculosis and individuals at high or low risk of Mycobacterium tuberculosis infection. Am J Infect Control 31: 347-353.
Fleischmann RD, Alland D, Eisen JA, Carpenter L, White O, Peterson J, DeBoy R, Dodson R, Gwinn M, Haft D, Hickey E, Kolonay JF, Nelson WC, Umayam LA, Ermolaeva M, Salzberg SL, Delcher A, Utterback T, Weidman J, Khouri H, Gill J, Mikula A, Bishai W, Jacobs Jr WR, Venter JC, Fraser CM 2002. Whole-genome comparison of Mycobacterium tuberculosis clinical and laboratory strains. J Bacteriol 184: 5479-5490.
Fonseca CT, Cunha-Neto E, Kalil J, de Jesus AR, Correa-Oliveira R, Carvalho EM, Oliveira SC 2004. Identification of immunodominant epitopes of Schistosoma mansoni vaccine candidate antigens using human T cells. Mem Inst Oswaldo Cruz 99 (Suppl. I): 63-66.
Fonseca SG, Coutinho-Silva A, Fonseca LA, Segurado AC, Moraes SL, Rodrigues H, Hammer J, Kallás EG, Sidney J, Sette A, Kalil J, Cunha-Neto E 2006. Identification of novel consensus CD4 T-cell epitopes from clade B HIV-1 whole genome that are frequently recognized by HIV-1 infected patients. AIDS 20: 2263-2273.
Fonseca SG, Moins-Teisserenc H, Clave E, Ianni B, Nunes VL, Mady C, Iwai LK, Sette A, Sidney J, Marin ML, Goldberg AC, Guilherme L, Charron D, Toubert A, Kalil J, Cunha-Neto E 2005. Identification of multiple HLA-A*0201-restricted cruzipain and FL-160 CD8+ epitopes recognized by T cells from chronically Trypanosoma cruzi-infected patients. Microbes Infect 7: 688-697.
Girardi E, Angeletti C, Puro V, Sorrentino R, Magnavita N, Vincenti D, Carrara S, Butera O, Ciufoli AM, Squarcione S, Ippolito G, Goletti D 2009. Estimating diagnostic accuracy of tests for latent tuberculosis infection without a gold standard among healthcare workers. Euro Surveill 14: 19373.
Girardi E, Raviglione MC, Antonucci G, Godfrey-Faussett P, Ippolito G 2000. Impact of the HIV epidemic on the spread of other diseases: the case of tuberculosis. AIDS 14 (Suppl. 3): S47-S56.
Idh J, Abate E, Westman A, Elias D, Janols H, Gelaw A, Getachew A, Alemu S, Aseffa A, Britton S, Stendahl O, Schön T 2010. Kinetics of the QuantiFERON-TB Gold In-Tube test during treatment of patients with sputum smear-positive tuberculosis in relation to initial TST result and severity of disease. Scand J Infect Dis 42: 650-657.
Iwai LK, Yoshida M, Sidney J, Shikanai-Yasuda MA, Goldberg AC, Juliano MA, Hammer J, Juliano L, Sette A, Kalil J, Travassos LR, Cunha-Neto E 2003. In silico prediction of peptides binding to multiple HLA-DR molecules accurately identifies immunodominant epitopes from gp43 of Paracoccidioides brasiliensis frequently recognized in primary peripheral blood mononuclear cell responses from sensitized individuals. Mol Med 9: 209-219.
Lewinsohn DA, Lobato MN, Jereb JA 2010. Interferon-gamma release assays: new diagnostic tests for Mycobacterium tuberculosis infection and their use in children. Curr Opin Pediatr 22: 71-76.
Lewthwaite JC, Coates AR, Tormay P, Singh M, Mascagni P, Poole S, Roberts M, Sharp L, Henderson B 2001. Mycobacterium tuberculosis chaperonin 60.1 is a more potent cytokine stimulator than chaperonin 60.2 (Hsp 65) and contains a CD14-binding domain. Infect Immun 69: 7349-7355.
Meister GE, Roberts CG, Berzofsky JA, de Groot AS 1995. Two novel T cell epitope prediction algorithms based on MHC-binding motifs; comparison of predicted and published epitopes from Mycobacterium tuberculosis and HIV protein sequences. Vaccine 13: 581-591.
Mendelson M, Walters S, Smith I, Kaplan G 2005. Strain-specific mycobacterial lipids and the stimulation of protective immunity to tuberculosis. Tuberculosis 85: 407-413.
Rammensee HG 1995. Chemistry of peptides associated with MHC class I and class II molecules. Curr Opin Immunol 7: 85-96.
Redelman-Sidi G, Sepkowitz KA 2013. IFN-γ release assays in the diagnosis of latent tuberculosis infection among immunocompromised adults. Am J Respir Crit Care Med 188: 422-431.
Richeldi L, Losi M, D'Amico R, Luppi M, Ferrari A, Mussini C, Codeluppi M, Cocchi S, Prati F, Paci V, Meacci M, Meccugni B, Rumpianesi F, Roversi P, Cerri S, Luppi F, Ferrara G, Latorre I, Gerunda GE, Torelli G, Esposito R, Fabbri LM 2009. Performance of tests for latent tuberculosis in different groups of immunocompromised patients. Chest 136: 198-204.
Schroers R, Huang XF, Hammer J, Zhang J, Chen SY 2002. Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells. Cancer Res 62: 2600-2605.
Shinnick TM 1987. The 65-kilodalton antigen of Mycobacterium tuberculosis. J Bacteriol 169: 1080-1088.
Soborg B, Ruhwald M, Hetland ML, Jacobsen S, Andersen AB, Milman N, Thomsen VO, Jensen DV, Koch A, Wohlfahrt J, Ravn P 2009. Comparison of screening procedures for Mycobacterium tuberculosis infection among patients with inflammatory diseases. J Rheumatol 36: 1876-1884.
Stewart GR, Robertson BD, Young DB 2003. Tuberculosis: a problem with persistence. Nat Rev Microbiol 1: 97-105.
Sturniolo T, Bono E, Ding J, Raddrizzani L, Tuereci O, Sahin U, Braxenthaler M, Gallazzi F, Protti MP, Sinigaglia F, Hammer J 1999. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat Biotechnol 17: 555-561.
Sun Y, Iglesias E, Samri A, Kamkamidze G, Decoville T, Carcelain G, Autran B 2003. A systematic comparison of methods to measure HIV-1 specific CD8 T cells. J Immunol Methods 272: 23-34.
Tanghe A, Lefèvre P, Denis O, D'Souza S, Braibant M, Lozes E, Singh M, Montgomery D, Content J, Huygen K 1999. Immunogenicity and protective efficacy of tuberculosis DNA vaccines encoding putative phosphate transport receptors. J Immunol 162: 1113-1119.
Wilkinson KA, Newton SM, Stewart GR, Martineau AR, Patel J, Sullivan SM, Herrmann JL, Neyrolles O, Young DB, Wilkinson RJ 2009. Genetic determination of the effect of post-translational modification on the innate immune response to the 19 kDa lipoprotein of Mycobacterium tuberculosis. BMC Microbiol 9: 93.
Xie J, Lu W, Samri A, Costagliola D, Schnuriger A, da Silva BC, Blanc C, Larsen M, Theodorou I, Rouzioux C, Autran B, ALT-ANRS-CO15 study group 2010. Distinct differentiation profiles of HIV-Gag and Nef-specific central memory CD8+ T cells associated with HLA-B57/5801 and virus control. AIDS 24: 2323-2329.
Zhang H, Qiu Z, Jiao Y, Wang A, Li T 2009. HIV-specific CD8+ T cell responses to HXB2 Gag and Nef peptide pools in Chinese HIV/AIDS patients. Sci China C Life Sci 52: 841-846.
Zhang S, Shao L, Mo L, Chen J, Wang F, Meng C, Zhong M, Qiu L, Wu M, Weng X, Zhang W 2010. Evaluation of gamma interferon release assays using Mycobacterium tuberculosis antigens for diagnosis of latent and active tuberculosis in Mycobacterium bovis BCG-vaccinated populations. Clin Vaccine Immunol 17: 1985-1990.


text:
Dear Prime Minister,
I write this letter with hope and fear. You have been elected with a majority that is unheard of in an era of coalition politics. Your cult following and your promise of a better future is an envy to any world leader. Most of us have taken everything you said at face value, as to the intent and integrity. Corruption has come down and accountability is higher than before.
However, the poll that you conducted on the 'demonetisation' issue and also claiming victory unnerved me. Do you think you actually needed to do that? Is that the evidence you have to support your policies? Does it behove the leader of the world's largest democracy to fall back into such gimmickry as popular support? When the world looks at this poll and its methodology, you and we will be a laughing stock. I would be seriously worried if you actually believe in what you are saying based on these results.
Sir, the demonetisation decision is one of the bravest decisions I have seen in the last 3 decades. It takes some guts to hurt your own. But brave need not be the best and intent need not mean efficient. At this point, you are surrounded by a sycophantic bureaucracy and leadership that may not tell you the truth. Those who advised you on this poll are seeking your downfall. They aren't your friends.
The total jobs created in 2015 were 1.35 lacs against 12.56 lacs in 2009 and 4.93 lacs in 2014. In fact, in the 4th quarter of 2015, we lost 20,000 jobs. The demonetisation will further the job losses. This isn't an 'inconvenience', but a lethal blow to families. Speak to any economist or industry head and he will tell you. It is time to take corrective measures. It is time to boost the economy, revive businesses and invest in job creation.
Sir, there is no bravado in winning a battle to lose the war. I as an Indian want you to succeed. A surgical strike is easy, a prolonged war is difficult. This is a war India cannot lose. What you do in the next three months will determine your re-election in 2019. And your app would play no role in those elections. But your actions would. Your humility would. Your ability to listen to alternate voices would. Your conviction to talk to critics, economists and act on them would.
I hope that those who surround you let this letter reach you. Would you want to be our prime minister in 2019 too? Rather, do you have it in you to be re-elected our prime minister in 2019?
Warm regards
An Indian. A human.


text:
May they see get next memphis cheap nfl jerseys
Business June 6, 2019
He has had trouble with consistency in New York, but no one could shine in the circus that that team was when he was with them. South Regional – No. The Bengals are good enough that they should be able to contain some of ...Read More


text:
November 19, 2019, 12:55 pmRJ BarrettSF, New York Knicks
RJ Barrett (sprained left thumb) is listed as probable for Wednesday's game against the Sixers.
Barrett has had a solid season in the counting stats this year with 15.8 points, 5.6 rebounds, 3.6 assists, 1.2 threes and 1.3 steals per game. Of course the caveat being that those numbers come with some of the worst percentages in the league and 2.7 turnovers per game. Barrett will have every opportunity to fix those issues this year and remains a must-own on a bad Knicks team.
Source: Knicks PR on Twitter
Fantasy News
December 15, 2019, 3:37 pmNassir LittleSF, Portland Trail Blazers
Nassir Little (back spasms) is questionable for Monday's game.
Little didn't play in Portland's last game, though his playing time has been trending down since a short run in the starting five. He's not a fantasy option.
Source: Jamie Goldberg on Twitter
December 15, 2019, 3:36 pmIsaiah ThomasPG, Washington Wizards
Isaiah Thomas (left calf strain) has a "good chance" of returning on Monday.
Thomas has been out for 10 days, though it remains to be seen if he'll go right back into the starting five upon returning. He's been a much better fit, at least from a fantasy perspective, with the second unit. Ish Smith's value will take a hit.
Source: Fred Katz on Twitter
December 15, 2019, 3:34 pmMoritz WagnerPF, Washington Wizards
Scott Brooks deemed it unlikely that Moe Wagner (sprained ankle) would be able to play on Monday.
It'll be Wagner's second straight absence, and he's missing a great chance to put up numbers with Thomas Bryant sidelined. Ian Mahinmi will once again be the Wizards' only center on Monday and could get some big minutes against Detroit.
Source: Fred Katz on Twitter
December 15, 2019, 3:31 pmNicolas ClaxtonPF, Brooklyn Nets
Nicolas Claxton (left hamstring soreness) will not play on Sunday.
Claxton has been in and out of the rotation and isn't much of a redraft option at this point, though that can change. He'll need to get healthy first, obviously.
Source: NBA Injury Report
December 15, 2019, 2:44 pmPaul MillsapPF, Denver Nuggets
Paul Millsap (right quad strain) is being considered questionable on Sunday vs. the Knicks.
Millap missed Saturday night's game vs. the Thunder and he might be in danger of missing this one too. Stay tuned for updates closer to tip-off but if he does miss then expect Jerami Grant to once again start in his place.
Source: Denver Nuggets on Twitter
December 15, 2019, 2:42 pmJamal MurrayPG, Denver Nuggets
Jamal Murray (back soreness) is probable on Sunday vs. the Knicks.
Murray played a good game vs. the Thunder on Saturday night and it looks like he'll suit up for more of the same vs. the Knicks. He can be locked into all lineups against a very bad Knicks defense.
Source: Denver Nuggets on Twitter
December 15, 2019, 1:45 pmNikola VucevicC, Orlando Magic
Nikola Vucevic (right ankle sprain) will be available to play in Sunday's game vs. the Pelicans.
He'll be making his return after missing his last 11 games and fantasy owners should be very happy. They might work him back into the action slowly so don't be surprised if he doesn't play big minutes tonight but his return will send Khem Birch out of the rotation. Unfortunately, it will also impact Mo Bamba's value but he's still worth holding onto in most leagues.
Source: Adrian Wojnarowski on Twitter
December 15, 2019, 12:58 pmLuka DoncicPG-SF, Dallas Mavericks
Luka Doncic may be able to return "within a couple of weeks," according to a report from ESPN's Tim MacMahon.
MacMahon adds that Doncic is likely to miss Dallas' next four games. Jalen Brunson started the second half in Doncic's place last night and had a strong game overall with 17 points, seven rebounds and eight assists in 34 minutes, and he's the likely add in 12-team formats. Tim Hardaway Jr. will take on more of a scoring load and should be added where available as well. Kristaps Porzingis should get a big usage boost, while other players like Dorian Finney-Smith, Delon Wright, Seth Curry and JJ Barea will all get more minutes, though Wright is the only one of that bunch with enough upside to stand out in 12-team leagues. Doncic did not travel with the Mavs to Milwaukee and there is hope that he returns around Christmas.
Source: Tim MacMahon on Twitter
December 15, 2019, 11:49 amJoel EmbiidC, Philadelphia Sixers
Joel Embiid is being listed as doubtful with an upper respiratory illness for Sunday's matchup with the Nets.
Embiid had been rolling after playing really well in both games of a back-to-back set, so this obviously very disappointing for his owners. Al Horford (knee & hamstring soreness) is still listed as questionable for this one as well, putting the Sixers at risk of being incredibly thin in the middle. If neither are able to suit up, Kyle O'Quinn could be looking at a ton of minutes.
Source: Keith Pompey on Twitter
December 15, 2019, 10:39 amEric PaschallPF, Golden State Warriors
Eric Paschall (sore left hip) is being listed as questionable for Sunday's tilt against the Kings.
He went into Friday's game listed as doubtful, so while this is an upgrade for him, it still remains to be seen if he is able to suit up. If he can't go expect Marquese Chriss to continue picking up extra slack.
Source: NBA Injury Report